DGAP-News: Silvia Quandt&Cie. AG, Merchant&Investment Banking: healthcare industry is facing a global burst of, Top Picks are Draeger, Stada&Fresenius SE
(firmenpresse) - Silvia Quandt&Cie. AG, Merchant&Investment Banking / Key word(s): Research Update/Research Update
03.11.2010 11:40
---------------------------------------------------------------------------
Press release
Silvia Quandt Research: healthcare industry is facing a global burst of
growth
German companies benefit from high demand of emerging markets
The health care industry, health care services and goods are facing a world
wide burst of growth in the coming years. Since German health care
companies such as Bayer, Fresenius, Medical Care or Stada are well placed
in the international market they will benefit over proportionally. These
are the results of the current, comprehensive health care study of Silvia
Quandt Research GmbH, released in Frankfurt today.
According to Stefan Mühlbauer, Head of Life Science of Silvia Quandt
Research, the following reasons are boosting the growing global demand. On
the one hand the ageing population is spending an increasing part of their
income, however this will lead to a sharp increase of healthcare budgets
and rationalisation of the health care system of the industrialised
countries particularly in Germany. On the other hand emerging markets are
facing a serious demographic change. Furthermore in the countries with
growing wealth, health care services similar to those provided in
industrialized countries will gain more demand
German companies of the health care industry for example Dax-Companies
Bayer, Fresenius and Fresenius Medical Care are top companies in their
field and are placed excellently world wide according to Mühlbauer. In his
opinion the companies are going to benefit from the demonstrated global
burst of growth. Currently Mühlbauer is assuming the Draeger-share with a
target price of EUR71 Euros has the best opportunities on the stock market.
In addition he is classifying STADA (target price 27 Euros) the Fresenius
(target price 71 euros) and the Merck (target price 67 Euros) with a buy
recommendation.
About Silvia Quandt Research GmbH
Silvia Quandt Research GmbH, located in Frankfurt am Main, is a 100 per
cent subsidiary of Silvia Quandt&Cie. AG and produces financial analysis
on own behalf and invoice. With a qualified team of numerous analysts,
Silvia Quandt Research covers a wide range of sectors.
03.11.2010 11:40 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Datum: 03.11.2010 - 11:40 Uhr
Sprache: Deutsch
News-ID 32476
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Silvia Quandt&Cie. AG, Merchant&Investment Banking: healthcare industry is facing a global burst of, Top Picks are Draeger, Stada&Fresenius SE"
steht unter der journalistisch-redaktionellen Verantwortung von
Silvia Quandt&Cie. AG, Merchant&Investment Banking (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
